SCHEMBL13099551

SCHEMBL13099551

COc1ccc(NC(=O)[C@H]2CC=C[C@H]3CCN(c4ccccc4)C(=O)[C@@H]23)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 2/20 0.52
▸ OPRK1 P41145 2/20 0.49
▸ ACHE P22303 1/20 0.47
▸ BACE1 P56817 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ HTT P42858 2/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ SLC1A2 P43004 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ MAPT P10636 2/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ FPR2 P25090 2/20 0.42
▸ FPR1 P21462 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13108593 1.00 HCRTR1 (0.52) HCRTR1OPRK1ACHEBACE1USP2
SCHEMBL13108437 0.91 HCRTR1 (0.61) HCRTR1OPRK1ALDH1A1HTTPOLB
SCHEMBL13099548 0.91 HCRTR1 (0.61) HCRTR1OPRK1ALDH1A1HTTPOLB
SCHEMBL13108448 0.88 HCRTR1 (0.58) HCRTR1OPRK1ALDH1A1HTTPOLB
SCHEMBL13099584 0.88 HCRTR1 (0.54) HCRTR1OPRK1ALDH1A1HTTPOLB
SCHEMBL13108384 0.88 HCRTR1 (0.54) HCRTR1OPRK1ALDH1A1HTTPOLB
SCHEMBL13099597 0.88 HCRTR1 (0.58) HCRTR1OPRK1ALDH1A1HTTPOLB
SCHEMBL13108668 0.85 OPRK1 (0.55) HCRTR1OPRK1ALDH1A1HTTCYP2C19
SCHEMBL13099535 0.85 HCRTR1 (0.70) HCRTR1OPRK1ACHEBACE1USP2
SCHEMBL15743766 0.85 HCRTR1 (0.70) HCRTR1OPRK1ACHEBACE1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF KANSAS (US) 2014-08-28 — — US disclosed
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF KANSAS (US) 2014-08-28 — — US disclosed
US-8735391-B2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods UNIVERSITY OF KANSAS (US) 2014-05-27 — — US disclosed
US-8735391-B2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods UNIVERSITY OF KANSAS (US) 2014-05-27 — — US disclosed
US-20100256142-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF NORTH CAROLINA 2010-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256142-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS OPRM1, OPRK1, OPRL1 HCRTR1 14/4885OPRK1 2/4885ACHE 1770/4885
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS OPRM1, OPRK1, OPRD1 HCRTR1 33/4885OPRK1 2/4885ACHE 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback